Sarepta Therapeutics (MEX:SRPT) Moat Score: 6/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SRPT Sarepta Therapeutics Inc MEX:SRPT
36 GF Score
Price MXN294.00
GF Value MXN2,058.94
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Moat Score?

Sarepta Therapeutics MEX:SRPT 36 Moat Score is 6 as of Jul. 14, 2026. GuruFocus rates MEX:SRPT with a GF Score™ of 36/100 and a GF Value™ of MXN2,058.94 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,396 Biotechnology companies, Sarepta Therapeutics ranks better than 98.93% on this metric.

Sarepta Therapeutics has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Sarepta Therapeutics has Narrow Moat: Sarepta has a strong narrow moat due to its valuable intellectual property and patents in the gene therapy space. It has a solid market position in rare disease treatments, supported by significant R&D capabilities. However, the competitive landscape in biotech and potential regulatory challenges prevent it from achieving a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sarepta Therapeutics might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Sarepta Therapeutics  (MEX:SRPT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sarepta Therapeutics Moat Score Related Terms

MEX:SRPT vs ZYME, BCAX, INVA: Moat Score Comparison

For the Biotechnology subindustry, Sarepta Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sarepta Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Moat Score falls into.


MEX:SRPT
36GF Score
Sarepta Therapeutics Inc MEX:SRPT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Sarepta Therapeutics (MEX:SRPT) has a Moat Score of 6 as of Jul. 14, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sarepta Therapeutics ranks #15 out of 1396 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Sarepta Therapeutics' Moat Score too high?
Sarepta Therapeutics' current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. Sarepta Therapeutics' value of 6 is 200% above this industry median. Based on the distribution chart, Sarepta Therapeutics ranks #15 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Moat Score compare to ZYME and BCAX?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #15 out of 1396 companies for Moat Score. This places Sarepta Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Sarepta Therapeutics' value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sarepta Therapeutics's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sarepta Therapeutics's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,058.94, compared to a current price of MXN294.00 — trading 85.7% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. Sarepta Therapeutics' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Moat Score is 6 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of MXN294.00 is trading 85.7% below its estimated GF Value™ of MXN2,058.94. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for MEX:SRPT:

  • Moat Score: 6
  • GF Value™: MXN2,058.94 vs. price of MXN294.00 (85.7% below fair value)
  • GF Score™: 36/100 with 5 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1396)

No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score

Get the complete analysis for MEX:SRPT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN294.00
Price
MXN2,058.94
GF Value